1. Hunder GG et al: The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33:1065, 1990
2. Jennette JC et al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. 37:187, 1994
3. Gardner-Medwin JM et al: Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360:1197, 2002
4. Gupta S et al: Cutaneous vasculitides: Clinico-pathological correlation. Indian J Dermatol Venereol Leprol75:356, 2009
5. Watts RA et al: What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 19:191, 2005
6. Ghersetich I et al: Cellular steps in pathogenesis of cutaneous necrotizing vasculitis. Clin Dermatol 17: 597, 1999
7. Banno S et al: Apoptotic cell death of neutrophils in development of skin lesions of patients with anaphylactoid purpura. J Dermatol 24:94, 1997
8. van Rossum AP et al: Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 54:986, 2006
9. Lotti TM et al: Langerhans' cells and cutaneous necrotizing vasculitis. Clin Dermatol 17:591, 1999
10. Pacheco LS, Sotto MN: Factor XIIIa+ dermal dendrocytes in erythema elevation diutinum and ordinary cutaneous leukocytoclastic vasculitis lesions. J Cutan Pathol 27:136, 2000
11. Comacchi C et al:γ/δ T lymphocytes and infection: Pathogenesis of leukocytoclastic cutaneous necrotizing vasculitis. Clin Dermatol 17:603, 1999
12. Soter NA et al: Cutaneous necrotizing venulitis: A sequential analysis of the morphological alterations occurring after mast cell degranulation in a patient with a unique syndrome. Clin Exp Immunol 32:46, 1978
13. Kano Y et al: Cellular and molecular dynamics in exercise-induced urticarial vasculitis lesions. Arch Dermatol 134:62, 1998
14. Sais G et al: Adhesion molecule expression and endothelial cell activation in cutaneous leukocytoclastic vasculitis: An immunohistologic and clinical study of 42 patients. Arch Dermatol 133:443, 1997
15. Fessatou S et al: Endothelian 1 levels in relation to clinical presentation and outcome of Henoch-Schönlein purpura. BMC Pediatr 8:33, 2008
16. Yildiz B et al: Increased serum levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in Henoch- Schonlein purpura. Tohoku J Exp Med 214:333, 2008
17. Zou CC et al: Plasma levels of matrix metalloproteinase-9 in Henoch-Schönlein purpura. Scand J Rheumatol 35:52, 2006
18. Wang L-J et al: Levels of intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 in children with Henoch-Schönlein purpura. J Microbiol Immunol Infect 39:109, 2006
19. Lin C-Y et al: Thrombopoietin and interleukin-6 levels in Henoch-Schönlein purpura. J Microbiol Immunol Infect 39: 476, 2006
20. Yang Y-H et al: The immunobiology of Henoch-Schönlein purpura. Autoimmun Rev 7:179, 2008
21. Tahan F et al: The role of chemokines in Henoch Schonlein purpura. Rheumatol Int 27:955, 2007
22. Yang Y-H et al: Circulating IgA from acute state of childhood Henoch-Schönlein purpura can enhance endothelial interleukin (IL)-8 production through MEK/ERK signalling pathway. Clin Exp Immunol 144:247, 2006
23. Besbas N et al: Thrombomodulin, tissue plasminogen activator, and plasminogen activator inhibitor-1 in Henoch-Schönlein purpura. Clin Exp Rheumatol 16:95, 1998
24. Prandota J et al: Impaired activation of the fibrinolytic system in children with Henoch-Schönlein purpura: Beneficial effect of
hydrocortisone plus Sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis.
Am J Ther 8:11, 2001
25. Bahrami S et al: Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol 142:155, 2006
26. Amoli MM et al: Henoch-Schönlein purpura and cutaneous leukocytoclastic angiitis exhibit different HLA-DRB1 associations. J Rheumatol 29:945, 2002
27. Ramos-Casals M et al: Vasculitis in systemic lupus erythematosus: Prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 85:95, 2006
28. Fukuda MV et al: Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus. Clin Rheumatol 28:301, 2009
29. Ramos-Casals M et al: Cutaneous vasculitis in primary Sjögren syndrome: Classification and clinical significance of 52 patients. Medicine (Baltimore) 83:96, 2004
30. Solans-Laqué R et al: Paraneoplastic vasculitis in patients with solid tumors: Report of 15 cases. J Rheumatol 35:294, 2008
31. Cohen P, Guillevin L: Vascularites associées aux infections virales. Presse Med 33:1371, 2004
32. Trejo O et al: Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 80:252, 2001
33. Chen K-R et al: Cutaneous vasculitis in Behçet's disease: A clinical and histopathologic study of 20 patients. J Am Acad Dermatol 36:689, 1997
34. Kawakami T et al: Clinical and histopathologic features of 8 patients with microscopic polyangiitis including two with a slowly progressive clinical course. J Am Acad Dermatol 57:840, 2007
35. Niiyama S et al: Dermatological manifestations associated with microscopic polyangiitis. Rheumatol Int 28:593, 2008
36. Irvine AD et al: Microscopic polyangiitis: Delineation of a cutaneous-limited variant associated with antimyeloperoxidase autoantibody. Arch Dermatol 133:474, 1997
37. Burden AD et al: IgA class anticardiolipin antibodies in cutaneous leukocytoclasic vasculitis. J Am Acad Dermatol 35:411, 1996
38. Kawakami T et al: High titer of serum antiphospholipid antibody levels in adult Henoch-Schönlein purpura and cutaneous leukocytoclastic angiitis. Arthritis Rheum 59:561, 2008.
39. Acland KM et al: Livedoid vasculitis: A manifestation of antiphospholipid syndrome? Br J Dermatol 140:131, 1999
40. ten Holder SM, Joy MS, Falk RJ: Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 36:130, 2002
41. Chastain MA et al:
Propylthiouracil hypersensitivity: Report of two patients with vasculitis and review of the literature.
J Am Acad Dermatol 41:757, 1999
42. Ramos-Casals M et al: Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine (Baltimore) 86:242, 2007
43. Ramos-Casals M et al: Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 10:442, 2008
44. Trapani S et al: Henoch Schönlein purpura in childhood: Epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 35:143, 2005
45. Diehl MP, Harrington T, Olenginski T: Elderly-onset Henoch Schonlein purpura: A case series and review of the literature. J A Geriatr Soc 56:2157, 2008
46. Peru H, et al: Henoch Schonlein in childhood: Clinical analysis of 254 cases over a 3-year period. Clin Rheumatol 27:1087, 2008
47. Al Sufyani MA: Acute hemorrhagic edema of infancy: Unusual scarring and review of the English language literature. Int J Dermatol 48:617, 2009
48. Soter NA: Urticarial venulitis/vasculitis. In: Urticaria and Angiodema, edited by AP Kaplan, MW Greaves. New York, Informa Healthcare, 2009, p. 373
49. Davis MD et al: Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol 38:899, 1998
50. Dincy CV et al: Clinicopathologic profile of normocomplementemic and hypocomplementemic urticarial vasculitis: A study from South India. J Eur Acad Dermatol Venereol 22:789, 2008
51. Lipsker D et al: The Schnitzler syndrome: Four new cases and review of the literature. Medicine (Baltimore) 80:37, 2001
52. Baselga E et al: Detection of Mycobacterium tuberculosis DNA in lobular granulomatous panniculitis (erythema induratum-nodular vasculitis). Arch Dermatol 133:457, 1997
53. Schneider JW, Jordaan HF: The histopathologic spectrum of erythema induratum of Bazin. Am J Dermatopathol 19:323, 1997
54. Fernandes SS et al: Erythema induration and chronic hepatitis C infection. J Clin Virol 44:333, 2009
55. Boyvat A et al: Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol 143:840, 2000
56. Hairston BR et al: Livedoid vasculopathy: Further evidence for procoagulant pathogenesis. Arch Dermatol 142: 1413, 2006
57. Khenifer S et al: Livedoid vasculopathy: Thrombotic or inflammatory disease? Clin Exp Dermatol 35(7):693-698, 2010
58. Matsumura Y et al: Sneddon syndrome with multiple cerebral infarctions 12 years after the onset of livedo vasculitis: A possible involvement of platelet activation. J Dermatol 28:508, 2001
59. Francès C et al: Sneddon syndrome with or without antiphospholipid antibodies: A comparative study in 46 patients. Medicine (Baltimore) 78:209, 1999
60. Kalashnikova LA et al: Antibodies to prothrombin in patients with Sneddon's syndrome. Neurology 53:223, 1999
61. Jang K-A et al: Hypereosinophilic syndrome presenting as cutaneous necrotizing eosinophilic vasculitis and Raynaud's phenomenon complicated by digital gangrene. Br J Dermatol 143:641, 2000
62. Chen K-R et al: Eosinophilic vasculitis in connective tissue disease. J Am Acad Dermatol 35:173, 1996
63. D'Cruz DP et al: Autoantibodies in systemic lupus erythematosus and urticarial vasculitis. J Rheumatol 22:1669, 1995
64. Rovel-Guitera P et al: IgA antineutrophil cytoplasmic antibodies in cutaneous vasculitis. Br J Dermatol 143:99, 2000
65. Soter NA et al: Two distinct cellular patterns in cutaneous necrotizing angiitis. J Invest Dermatol 66:344, 1976
66. Egan CA et al: IgA1 is the major IgA subclass in cutaneous blood vessels in Henoch-Schönlein purpura. Br J Dermatol 141:859, 1999
67. Ong CS, Benson EM: Successful treatment of chronic leukocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol 143:447, 2000
68. Mang R, Ruzicka T, Stege H: Therapy for severe necrotizing vasculitis with
infliximab.
J Am Acad Dermatol 51:321, 2004
69. Donnithorne KJ et al:
Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura.
J Pediatr 155:136, 2009
70. Chung L et al: Successful use of
rituximab for cutaneous vasculitis.
Arch Dermatol 142:1407, 2006
71. Worm M, Sterry W, Kolde G:
Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis.
Br J Dermatol 143:1324, 2000
72. Zeni P, Finger E, Scheinberg MA: Successful use of
rituximab in a patient with recalcitrant livedoid vasculopathy.
Ann Rheum Dis 67:1055, 2008
73. Deng A et al: Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 142:1466, 2006
74. Juan W-H et al: Livedoid vasculopathy: Long-term follow-up results following hyperbaric
oxygen therapy.
Br J Dermatol 154:251, 2006